GH Research Shares Rise Ahead of Release of Clinical-Trial Results

Dow Jones02-01

By Connor Hart

Shares of GH Research climbed after the company said it would provide data from a trial of its drug for treatment-resistant depression.

The stock rose 5.2%, to $11.15, in after-hours trading on Friday. Shares ended the regular session 9.4% higher, at $10.60, putting them up 39% in the past year.

The biopharmaceutical company said it would host a webcast Monday morning to discuss data from its Phase 2b trial of its lead product candidate, GH001.

In December 2021, the Dublin company said the drug met the primary endpoint of the Phase 2 part of its Phase 1/2 trial, as seven out of eight patients achieved remission after a week of using the treatment.

The company said it believes that GH001 has the potential to change the way treatment-resistant depression is managed.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

January 31, 2025 17:43 ET (22:43 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2508913784?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-01 06:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2508913784","market":"sg","top_or_hot":-1,"title":"GH Research Shares Rise Ahead of Release of Clinical-Trial Results","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of GH Research climbed after the company said it would provide data from a trial of its drug for treatment-resistant depression. \n</p>\n<p>\n  The stock rose 5.2%, to $11.15, in after-hours trading on Friday. Shares ended the regular session 9.4% higher, at $10.60, putting them up 39% in the past year. \n</p>\n<p>\n  The biopharmaceutical company said it would host a webcast Monday morning to discuss data from its Phase 2b trial of its lead product candidate, GH001. \n</p>\n<p>\n  In December 2021, the Dublin company said the drug met the primary endpoint of the Phase 2 part of its Phase 1/2 trial, as seven out of eight patients achieved remission after a week of using the treatment. \n</p>\n<p>\n  The company said it believes that GH001 has the potential to change the way treatment-resistant depression is managed. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 31, 2025 17:43 ET (22:43 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GH Research Shares Rise Ahead of Release of Clinical-Trial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGH Research Shares Rise Ahead of Release of Clinical-Trial Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-02-01 06:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Connor Hart \n\n\n \n\n\n  Shares of GH Research climbed after the company said it would provide data from a trial of its drug for treatment-resistant depression. \n\n\n  The stock rose 5.2%, to $11.15, in ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4535","symbol_name":"淡马锡持仓","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2508913784","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2508913784","pubTimestamp":1738363380,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of GH Research climbed after the company said it would provide data from a trial of its drug for treatment-resistant depression.The stock rose 5.2%, to $11.15, in after-hours trading on Friday. Shares ended the regular session 9.4% higher, at $10.60, putting them up 39% in the past year.The biopharmaceutical company said it would host a webcast Monday morning to discuss data from its Phase 2b trial of its lead product candidate, GH001.In December 2021, the Dublin company said the drug met the primary endpoint of the Phase 2 part of its Phase 1/2 trial, as seven out of eight patients achieved remission after a week of using the treatment.The company said it believes that GH001 has the potential to change the way treatment-resistant depression is managed.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4535":"淡马锡持仓","BK4551":"寇图资本持仓","BK4585":"ETF&股票定投概念","GH":"Guardant Health Inc.","BK4539":"次新股","BK4588":"碎股","GHRS":"GH Research PLC","BK4007":"制药","BK4196":"保健护理服务"},"translate_title":"GH Research股价在临床试验结果发布前上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GH":1,"GHRS":0.9},"content_text":"By Connor Hart \n\n\n \n\n\n  Shares of GH Research climbed after the company said it would provide data from a trial of its drug for treatment-resistant depression. \n\n\n  The stock rose 5.2%, to $11.15, in after-hours trading on Friday. Shares ended the regular session 9.4% higher, at $10.60, putting them up 39% in the past year. \n\n\n  The biopharmaceutical company said it would host a webcast Monday morning to discuss data from its Phase 2b trial of its lead product candidate, GH001. \n\n\n  In December 2021, the Dublin company said the drug met the primary endpoint of the Phase 2 part of its Phase 1/2 trial, as seven out of eight patients achieved remission after a week of using the treatment. \n\n\n  The company said it believes that GH001 has the potential to change the way treatment-resistant depression is managed. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 31, 2025 17:43 ET (22:43 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2508913784"}